![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 14
Zeitschriftenartikel
Nitz, Ulrike; Gluz, Oleg; Graeser, Monika; Christgen, Matthias; Kuemmel, Sherko; Grischke, Eva-Maria; Braun, Michael; Augustin, Doris; Potenberg, Jochem; Krauss, Katja; Schumacher, Claudia; Forstbauer, Helmut; Reimer, Toralf; Stefek, Andrea; Fischer, Hans Holger; Pelz, Enrico; Eulenburg, Christine zu; Kates, Ronald; Würstlein, Rachel; Kreipe, Hans Heinrich und Harbeck, Nadia
(2022):
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
In: Lancet Oncology, Bd. 23, Nr. 5: S. 625-635
Gluz, Oleg; Nitz, Ulrike; Kolberg-Liedtke, Cornelia; Prat, Aleix; Christgen, Matthias; Kuemmel, Sherko; Mohammadian, Mohammad Parsa; Gebauer, Daniel; Kates, Ronald; Pare, Laia; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Warm, Mathias; Hackmann, John; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Wuerstlein, Rachel; Graeser, Monika; Pelz, Enrico; Jozwiak, Katarzyna; Zu Eulenburg, Christine; Kreipe, Hans Heinrich und Harbeck, Nadia
(2022):
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial.
In: Clinical Cancer Research, Bd. 28, Nr. 22: S. 4995-5003
Kolberg-Liedtke, Cornelia; Feuerhake, Friedrich; Garke, Madlen; Christgen, Matthias; Kates, Ronald; Grischke, Eva Maria; Forstbauer, Helmut; Braun, Michael; Warm, Mathias; Hackmann, John; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Kuemmel, Sherko; Wuerstlein, Rachel; Graeser, Monika; Nitz, Ulrike; Kreipe, Hans; Gluz, Oleg und Harbeck, Nadia
(2022):
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
In: Breast Cancer Research, Bd. 24, Nr. 1, 58
Nitz, Ulrike A.; Gluz, Oleg; Kümmel, Sherko; Christgen, Matthias; Braun, Michael; Aktas, Bahriye; Lüdtke-Heckenkamp, Kerstin; Forstbauer, Helmut; Grischke, Eva-Maria; Schumacher, Claudia; Darsow, Maren; Krauss, Katja; Nuding, Benno; Thill, Marc; Potenberg, Jochem; Uleer, Christoph; Warm, Mathias; Fischer, Hans Holger; Malter, Wolfram; Hauptmann, Michael; Kates, Ronald E.; Gräser, Monika; Würstlein, Rachel; Shak, Steven; Baehner, Frederick; Kreipe, Hans H. und Harbeck, Nadia
(2022):
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HP2-Early Breast Cancer.
In: Journal of Clinical Oncology, Bd. 40, Nr. 23: S. 2557-2567
Trapp, Elisabeth K.; Fasching, Peter A.; Fehm, Tanja; Schneeweiss, Andreas; Mueller, Volkmar; Harbeck, Nadia; Lorenz, Ralf; Schumacher, Claudia; Heinrich, Georg; Schochter, Fabienne; de Gregorio, Amelie; Tzschaschel, Marie; Rack, Brigitte; Janni, Wolfgang und Friedl, Thomas W. P.
(2022):
Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A Trial.
In: Cancers, Bd. 14, Nr. 16, 3949
Graeser, Monika; Feuerhake, Friedrich; Gluz, Oleg; Volk, Valery; Hauptmann, Michael; Jozwiak, Katarzyna; Christgen, Matthias; Kuemmel, Sherko; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Warm, Mathias; Hackmann, John; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Kolberg-Liedtke, Cornelia; Kates, Ronald; Wuerstlein, Rachel; Nitz, Ulrike; Kreipe, Hans Heinrich und Harbeck, Nadia
(2021):
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.
In: Journal for Immunotherapy of Cancer, Bd. 9, Nr. 5, e002198
Graeser, Monika; Harbeck, Nadia; Gluz, Oleg; Wuerstlein, Rachel; Eulenburg, Christine zu; Schumacher, Claudia; Grischke, Eva -Maria; Forstbauer, Helmut; Dimpfl, Moritz; Braun, Michael; Christgen, Matthias; Kreipe, Hans Heinrich; Potenberg, Jochem; Schumann, Raquel von; Aktas, Bahriye; Kolberg-Liedtke, Cornelia; Kuemmel, Sherko und Nitz, Ulrike
(2021):
The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials.
In: Breast, Bd. 59: S. 58-66
Graeser, Monika; Schrading, Simone; Gluz, Oleg; Strobel, Kevin; Wuerstlein, Rachel; Kuemmel, Sherko; Schumacher, Claudia; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Christgen, Matthias; Adams, Jascha; Nitzsche, Henrik; Just, Marianne; Fischer, Hans Holger; Aktas, Bahriye; Potenberg, Jochem; Schumann, Raquel von; Kolberg-Liedtke, Cornelia; Harbeck, Nadia; Kuhl, Christiane K. und Nitz, Ulrike
(2021):
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.
In: International Journal of Cancer, Bd. 148, Nr. 10: S. 2614-2627
Grote, Isabel; Bartels, Stephan; Kandt, Leonie; Bollmann, Laura; Christgen, Henriette; Gronewold, Malte; Raap, Mieke; Lehmann, Ulrich; Gluz, Oleg; Nitz, Ulrike; Kuemmel, Sherko; Zu Eulenburg, Christine; Braun, Michael; Aktas, Bahriye; Grischke, Eva-Maria; Schumacher, Claudia; Luedtke-Heckenkamp, Kerstin; Kates, Ronald; Wuerstlein, Rachel; Graeser, Monika; Harbeck, Nadia; Christgen, Matthias und Kreipe, Hans
(2021):
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.
In: Cancer Medicine, Bd. 10, Nr. 23: S. 8581-8594
Harbeck, Nadia; Schumann, Raquel von; Kates, Ronald Ernest; Braun, Michael; Kuemmel, Sherko; Schumacher, Claudia; Potenberg, Jochem; Malter, Wolfram; Augustin, Doris; Aktas, Bahriye; Forstbauer, Helmut; Tio, Joke; Grischke, Eva-Maria; Biehl, Claudia; Liedtke, Cornelia; Haas, Sanne Lysbet de; Deurloo, Regula; Wuerstlein, Rachel; Kreipe, Hans Heinrich und Gluz, Oleg
(2021):
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.
In: Cancers, Bd. 13, Nr. 19, 4884
Gluz, Oleg; Kolberg-Liedtke, Cornelia; Prat, Aleix; Christgen, Matthias; Gebauer, Daniel; Kates, Ronald; Pare, Laia; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Warm, Mathias; Hackmann, John; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Kuemmel, Sherko; Würstlein, Rachel; Pelz, Enrico; Nitz, Ulrike; Kreipe, Hans Heinrich und Harbeck, Nadia
(2020):
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
In: International Journal of Cancer, Bd. 146, Nr. 1: S. 262-271
Nitz, Ulrike; Gluz, Oleg; Kreipe, Hans H.; Christgen, Matthias; Kuemmel, Sherko; Baehner, Frederick L.; Shak, Steven; Aktas, Bahriye; Braun, Michael; Ludtke-Heckenkamp, Kerstin; Forstbauer, Helmut; Grischke, Eva-Maria; Nuding, Benno; Darsow, Maren; Schumacher, Claudia; Krauss, Katja; Malter, Wolfram; Thill, Marc; Warm, Mathias; Würstlein, Rachel; Kates, Ronald E. und Harbeck, Nadia
(2020):
The run-in phase of the prospective WSG-ADAPT HR+/HER2-trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer.
In: Therapeutic Advances in Medical Oncology, Bd. 12: S. 1-9
[PDF, 531kB]
Gluz, Oleg; Nitz, Ulrike; Liedtke, Cornelia; Christgen, Matthias; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Warm, Mathias; Hackmann, John; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Bangemann, Nikola; Lindner, Christoph; Kuemmel, Sherko; Clemens, Michael; Potenberg, Jochem; Staib, Peter; Kohls, Andreas; Schumann, Raquel von und Harbeck, Nadia
(2018):
Comparison of Neoadjuvant Nab-Paclitaxe plus Carboplatin vs Nab-Paclitaxe plus Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
In: Jnci-Journal of the National Cancer Institute, Bd. 110, Nr. 6, djx258: S. 628-637
Harbeck, Nadia; Gluz, Oleg; Christgen, Matthias; Kates, Ronald Ernest; Braun, Michael; Küemmel, Sherko; Schumacher, Claudia; Potenberg, Jochem; Krämer, Stefan; Kleine-Tebbe, Anke; Augustin, Doris; Aktas, Bahriye; Forstbauer, Helmut; Tio, Joke; Schumann, Raquel von; Liedtke, Cornelia; Grischke, Eva-Maria; Schumacher, Johannes; Würstlein, Rachel; Kreipe, Hans Heinrich und Nitz, Ulrike Anneliese
(2017):
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
In: Journal of Clinical Oncology, Bd. 35, Nr. 26: S. 3046-3056